Evercore ISI Group analyst Mark Mahaney maintains Snap (NYSE:SNAP) with a In-Line and raises the price target from $14 to $17.
Junshi Biosciences and Coherus Announced FDA Has Been Unable to Travel to China to Conduct the Required Site Inspection Resulting in Delayed Action on the BLA for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS) today announced that the companies have not received an action letter from the U.S.